Development of the R263K Mutation to Dolutegravir in an HIV-1 Subtype D Virus Harboring 3 Class-Drug Resistance

Dolutegravir (DTG), a second-generation integrase strand-transfer inhibitor (INSTI), is equivalent or superior to current non-nucleotide reverse transcriptase inhibitors (NNRTIs), protease inhibitors (PIs), and first-generation INSTI-based antiretroviral regimens (ARVs). It has the potential to make...

Descripción completa

Detalles Bibliográficos
Autores principales: Ahmed, N, Flavell, S, Ferns, B, Frampton, D, Edwards, S G, Miller, R F, Grant, P, Nastouli, E, Gupta, R K
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2018
Materias:
ID Case
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6329901/
https://www.ncbi.nlm.nih.gov/pubmed/30648124
http://dx.doi.org/10.1093/ofid/ofy329

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6329901/
https://www.ncbi.nlm.nih.gov/pubmed/30648124
http://dx.doi.org/10.1093/ofid/ofy329

Ejemplares similares